Axsome Therapeutics (AXSM) total debt

Total debt · fiscal 2025
$218.11M

Axsome Therapeutics (AXSM) carried total debt of $218.11M at the end of fiscal 2025 (December 31, 2025). That is 13.0% higher than the $192.96M of fiscal 2024. Figures as of 18 Nov 2026, 02:58 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total debt, fiscal 2025
$218.11M
Change on fiscal 2024
+13.0%
Growth, 5 years
+35.2% a year
Highest on record
$218.11Mfiscal 2025
Lowest on record
$6.91Mfiscal 2018
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Axsome Therapeutics total debt, in more detail

Over the five fiscal years to 2025 total debt grew at a compound 35.2% a year. Across the 10 fiscal years on record (2016–2025), the highest was $218.11M in fiscal 2025 and the lowest $6.91M in fiscal 2018.

Total debt was 2.5× shareholders' equity at the end of fiscal 2025.

History · 10 fiscal years

Total debt by fiscal year

Axsome Therapeutics total debt, year by year

Axsome Therapeutics (AXSM) total debt by fiscal year
Fiscal yearTotal debtChangeYear endedDebt ÷ equity
2025$218.11M 13.0% up2.5×
2024$192.96M 3.5% up3.4×
2023$186.37M 96.8% up1.0×
2022$94.68M 92.9% up0.9×
2021$49.09M 1.6% up3.1×
2020$48.32M 142.4% up0.4×
2019$19.93M 188.5% up0.1×
2018$6.91M 30.4% down7.4×
2017$9.93M 2.0% up0.6×
2016$9.74M—0.5×

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

Total debt at health care companies of similar size

Total debt of Axsome Therapeutics and comparable companies
CompanyTotal debtFiscal year
Immunovant IMVT$72.00K2026
Axsome Therapeutics AXSM$218.11M2025
Chemed CHE$143.76M2025
Oruka Therapeutics ORKA$1.93M2025
Arrowhead Pharmaceuticals ARWR$1.00B2026
MSA Safety MSA$627.09M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AXSM

Axsome Therapeutics, figure by figure

Axsome Therapeutics (AXSM) overview: price, valuation and scorecardAll health care companies by market value

Axsome Therapeutics total debt: questions and answers

How much debt does Axsome Therapeutics have?

Axsome Therapeutics (AXSM) carried total debt of $218.11M at the end of fiscal 2025 (December 31, 2025). That is 13.0% higher than the $192.96M of fiscal 2024.

What is the growth rate of Axsome Therapeutics's total debt?

Over the five fiscal years to 2025 total debt grew at a compound 35.2% a year.

What are the highest and lowest total debt figures on record for Axsome Therapeutics?

Across the 10 fiscal years on record (2016–2025), the highest was $218.11M in fiscal 2025 and the lowest $6.91M in fiscal 2018.

How does Axsome Therapeutics's debt compare with its equity?

Total debt was 2.5× shareholders' equity at the end of fiscal 2025.

How is Axsome Therapeutics's total debt calculated?

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Axsome Therapeutics (AXSM) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/AXSM/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.